TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 08, 2023 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a late clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical needs in orthopedic disorders, today announced that the Abstract Selection Committee of the American College of Rheumatology (ACR) has accepted TLC's late-breaking abstract on TLC599 for oral presentation at ACR Convergence 2023. This will take place November 10–15 at the San Diego Convention Center in San Diego, California. TLC599 is a proprietary BioSeizer^® sustained release injectable in development for the treatment of osteoarthritis pain.

Read more at globenewswire.com